Glaukos Corporation Announces Second Quarter 2017 Financial Results
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced financial results for the second quarter ended June 30, 2017. Key highlights include: Achieved 45% net sales growth to $41.3 million in the second quarter of 2017, compared to $28.6 million in the second quarter of 2016. Increased